Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Natasha Carvalho Pandolfi"'
Autor:
Alexandre André Balieiro Anastácio da Costa, Elizabeth Santana dos Santos, Deborah Porto Cotrim, Natasha Carvalho Pandolfi, Marcelle Goldner Cesca, Henrique Mantoan, Solange Moraes Sanches, Adriana Regina Gonçalves Ribeiro, Louise de Brot, Graziele Bonvolim, Paulo Issamu Sanematsu, Ronaldo Pereira de Souza, Joyce Maria Lisboa Maya, Fabrício de Souza Castro, João Paulo da Nogueira Silveira Lima, Michael Jenwel Chen, Andrea Paiva Gadelha Guimarães, Glauco Baiocchi
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background Brain metastasis (BM) is a rare event in ovarian cancer patients. The current prognostic scores that have been used for other tumors do not account for specific characteristics of ovarian cancer, such as platinum sensitivity. Meth
Externí odkaz:
https://doaj.org/article/3129af1b1ece4e7e8fdad9ae1defc0e1
Autor:
Deborah Porto Cotrim, Adriana Regina Gonçalves Ribeiro, Daniele Paixão, Diogo Cordeiro de Queiroz Soares, Rima Jbili, Natasha Carvalho Pandolfi, Camila Cezana, Carine de Cássia Mauro, Henrique Mantoan, Graziele Bovolim, Louise de Brot, Giovana Tardin Torrezan, Dirce Maria Carraro, Glauco Baiocchi, Maria Nirvana da Cruz Formiga, Alexandre A. B. A. da Costa
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent among patients with ovarian carcinoma. However, these variants have not been extensively characterized in patients with ovarian cancer in Brazil. Met
Externí odkaz:
https://doaj.org/article/758ddea6326842a886213167f86a277b
Autor:
Marcelle Goldner, Solange Moraes Sanches, Noam Pondé, Natasha Carvalho Pandolfi, Debora Maciel, Julianne Lima
Publikováno v:
Expert review of anticancer therapy. 21(11)
Introduction: For decades, endocrine therapy has been the cornerstone of management for luminal breast cancer. Despite the substantial benefit derived by patients from endocrine therapy, primary and secondary resistances to endocrine therapy are seri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9d2b21df1f397c7ab2a5630dfbe55d5
https://pubmed.ncbi.nlm.nih.gov/34338570
https://pubmed.ncbi.nlm.nih.gov/34338570
Autor:
Natasha Carvalho Pandolfi, Fabrício de Souza Castro, Glauco Baiocchi, Andrea Paiva Gadelha Guimarães, Joyce Maria Lisboa Maya, Adriana Regina Gonçalves Ribeiro, Alexandre Andre Balieiro Anastacio da Costa, Marcelle Goldner Cesca, Ronaldo Pereira Souza, Michael Jenwel Chen, Paulo Issamu Sanematsu, Louise De Brot, Solange Moraes Sanches, João Paulo da Nogueira Silveira Lima, Graziele Bonvolim, Deborah Porto Cotrim, Elizabeth Santana dos Santos, Henrique Mantoan
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Background Brain metastasis (BM) is a rare event in ovarian cancer patients. The current prognostic scores that have been used for other tumors do not account for specific characteristics of ovarian cancer, such as platinum sensitivity. Methods This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b9005d85876b5d903bd45d7c2e2ab4
https://pubmed.ncbi.nlm.nih.gov/31805898
https://pubmed.ncbi.nlm.nih.gov/31805898
Autor:
Alexandre Andre Balieiro Anastacio da Costa, Graziele Bovolim, Louise De Brot, Carine de Cássia Mauro, Camila Cezana, Dirce Maria Carraro, Daniele Paixão, Rima Jbili, Adriana Regina Gonçalves Ribeiro, Giovana Tardin Torrezan, Maria Nirvana Formiga, Natasha Carvalho Pandolfi, Diogo Cordeiro de Queiroz Soares, Glauco Baiocchi, Henrique Mantoan, Deborah Porto Cotrim
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
BMC Cancer
Background BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent among patients with ovarian carcinoma. However, these variants have not been extensively characterized in patients with ovarian cancer in Brazil. Methods In t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6395621ec497f15f0a2f526902c91ce
https://doi.org/10.1186/s12885-018-5235-3
https://doi.org/10.1186/s12885-018-5235-3
Autor:
Vinicius Fernando Calsavara, Bruno Cezar de Mendonça Uchôa, Marcelle Goldner Cesca, Aldo Lourenço Abbade Dettino, Poliana de Andrade, Thiago Bueno Oliveira, Marcelo Corassa, Natasha Carvalho Pandolfi, Maysa Tamara Silveira Vilbert, Ricardo Lima Coelho, José Augusto Rinck
Publikováno v:
Journal of Clinical Oncology. 38:e17545-e17545
e17545 Background: Androgen receptor-targeted agents Abiraterone and Enzalutamide (Abi/Ez) prolonged overall survival in metastatic castration resistant prostate cancer (mCRPC). Patients with very-low serum testosterone levels seem to have less benef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c457eb7755d79cf3c596a0b0a8e8a7e7
https://doi.org/10.1200/jco.2020.38.15_suppl.e17545
https://doi.org/10.1200/jco.2020.38.15_suppl.e17545
Autor:
Daniel Garcia, Monique Celeste Tavares, João Pedreira Duprat, José Augusto Rinck, Marcos Rezende Teixeira, Thiago Bueno Oliveira, Natasha Carvalho Pandolfi, Milton Jos De Barros E Silva, Joao Paulo Sn Lima, Vinicius Fernando Calsavara
Publikováno v:
Journal of Clinical Oncology. 38:e22045-e22045
e22045 Background: Immune checkpoint blockade (ICB) has changed the natural history advanced melanoma (AM) with response rates about 40% and overall survival in 5 years of more than 30%. Interestingly, the site of metastasis may have impact on immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::185d9df660640fd1da42a0a4d98c0917
https://doi.org/10.1200/jco.2020.38.15_suppl.e22045
https://doi.org/10.1200/jco.2020.38.15_suppl.e22045
Autor:
Monique Celeste Tavares, Milton Jos De Barros E Silva, Vinicius Fernando Calsavara, José Augusto Rinck, Daniel Garcia, João Pedreira Duprat, Natasha Carvalho Pandolfi, Marcos Rezende Teixeira, Joao Paulo Sn Lima, Thiago Bueno Oliveira
Publikováno v:
Journal of Clinical Oncology. 38:10046-10046
10046 Background: Immune checkpoint blockade (ICB) has changed the natural history advanced melanoma (AM). Based on phase III trial, which used RECIST criteria, the complete response (CR) rate with anti-PD1 therapy is around 20%. In daily practice, P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5774a73de378e2d455efee540887ff3
https://doi.org/10.1200/jco.2020.38.15_suppl.10046
https://doi.org/10.1200/jco.2020.38.15_suppl.10046
Autor:
José Augusto Rinck, Aldo Lourenço Abbade Dettino, Natasha Carvalho Pandolfi, Thiago Bueno Oliveira, Marcelo Corassa, Vinicius Fernando Calsavara, Maysa Tamara Silveira Vilbert, Bruno Cezar de Mendonça Uchôa, Ricardo Lima Coelho, Poliana de Andrade, Marcelle Goldner Cesca
Publikováno v:
Journal of Clinical Oncology. 38:e17538-e17538
e17538 Background: mCRPC phenotype involves androgen-receptor signalling mechanisms that support the use of abiraterone/enzalutamide (Abi/Ez). These therapies improve overall survival (OS) and quality-of-life, with a favourable safety profile. There
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3157d9bae416914091c29fdd18435f0a
https://doi.org/10.1200/jco.2020.38.15_suppl.e17538
https://doi.org/10.1200/jco.2020.38.15_suppl.e17538
Autor:
Vinicius Fernando Calsavara, Marcelle Goldner Cesca, José Augusto Rinck, Natasha Carvalho Pandolfi, Aldo Lourenço Abbade Dettino, Ricardo Lima Coelho, Maysa Tamara Silveira Vilbert, Thiago Bueno Oliveira, Mariana Pinheiro Xerfan, Marcelo Corassa
Publikováno v:
Journal of Clinical Oncology. 38:202-202
202 Background: Survival outcomes for metastatic castration resistant prostate cancer (mCRPC) patients (pts) have greatly improved following the approval of Docetaxel and abiraterone(Abi)/enzalutamide(Ez). However, it is not clear who is likely to be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da8e0b7f4370d41970c26136466e958f
https://doi.org/10.1200/jco.2020.38.6_suppl.202
https://doi.org/10.1200/jco.2020.38.6_suppl.202